Ken Griffin Aptevo Therapeutics Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.17 - $0.38 $44,561 - $99,607
262,124 New
262,124 $47,000
Q2 2023

Aug 14, 2023
BUY
$1.34 - $2.08 $17,127 - $26,586
12,782 New
12,782 $18,000
Q4 2022

Feb 14, 2023
BUY
$2.0 - $138.16 $50,590 - $3.49 Million
25,295 Added 150.78%
42,071 $97,000
Q3 2022

Nov 14, 2022
BUY
$3.12 - $142.56 $52,341 - $2.39 Million
16,776 New
16,776 $51,000

About Aptevo Therapeutics Inc.

APVO Quotes by TradingView
  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $22.4M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email